The ALSFRSr predicts survival time in an ALS clinic population
暂无分享,去创建一个
P. Kaufmann | John L.P. Thompson | G. Levy | H. Mitsumoto | P. Gordon | L. Rowland | G. Levy | P. Kaufmann | J. L. Thompson | B. Levin | L. P. Rowland | H. Mitsumoto | V. Battista | G. Levy | J. L.P. Thompson | M. L. DelBene | V. Battista | P. H. Gordon | B. Levin | J. Thompson | M. DelBene | Gilberto Levy
[1] W. Bradley. A controlled trial of recombinant methionyl human BDNF in ALS , 1999, Neurology.
[2] W. Robberecht,et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. , 1998, Neurology.
[3] A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group. , 1996, Neurology.
[4] M. Naumann,et al. Disease progression in amyotrophic lateral sclerosis: Predictors of survival , 2002, Muscle & nerve.
[5] Mulder Dw. Clinical limits of amyotrophic lateral sclerosis. , 1982 .
[6] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. , 1996, Lancet.
[7] B. Brooks. Functional scales: Summary , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[8] M. Gaweł,et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. , 1997, Neurology.
[9] G. Parry,et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis , 2001, Neurology.
[10] G. Parry,et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. , 1996, Neurology.
[11] B. Everitt,et al. Statistical methods for rates and proportions , 1973 .
[12] P. Leigh,et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis , 1998, Neurology.
[13] D. Schoenfeld,et al. Functional outcome measures as clinical trial endpoints in ALS , 2004, Neurology.
[14] J. Cedarbaum,et al. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials , 1999, Journal of the Neurological Sciences.
[15] P. Sham,et al. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[16] M. Gaweł,et al. Effect of recombinant human insulin-like growth factor-I on progression of ALS , 1997, Neurology.
[17] D. Schoenfeld,et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis , 2003, Neurology.
[18] B. Brooks,et al. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.
[19] Bryan J. Traynor,et al. An outcome study of riluzole in amyotrophic lateral sclerosis , 2003, Journal of Neurology.
[20] G. Parry,et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis , 1996, Neurology.
[21] R. Sufit,et al. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[23] J. Cedarbaum,et al. Disease status and use of ventilatory support by ALS patients , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[24] J. Veldink,et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis , 2003, Annals of neurology.
[25] A. Al-Chalabi,et al. Early symptom progression rate is related to ALS outcome: a prospective population-based study. , 2002, Neurology.
[26] J. Cedarbaum,et al. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials , 1997, Journal of the Neurological Sciences.
[27] J. Cedarbaum,et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function , 1999, Journal of the Neurological Sciences.
[28] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[29] P. Leigh,et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.
[30] D.,et al. Regression Models and Life-Tables , 2022 .
[31] The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group. , 1996, Archives of neurology.